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Introduction
Early stage cervical cancer is treated with radical hysterec-
tomy with pelvic lymphadenectomy, and adjuvant therapy is 
recommended depending on the presence of risk factors for 
recurrence. Adjuvant radiotherapy is indicated for patients 
in the intermediate-risk group, which is characterized by the 
negative pelvic lymph nodes, parametrial invasion, and a 
combination of specific values of tumor size, lymphovascu-
lar space invasion (LVSI), and depth of stromal invasion. The 
evidence for the efficacy of adjuvant radiotherapy originates 
from a randomized study, the Gynecologic Oncology Group 
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Objective
This study aimed to investigate the prognosis of patients with intermediate-risk cervical cancer and to evaluate the 
necessity of adjuvant therapy.
Methods
We conducted a retrospective chart review of patients with stage IB–II cervical cancer who underwent type III radical 
hysterectomy with pelvic lymphadenectomy between 2008 and 2017. In our institution, radical hysterectomy is 
performed as an open surgery and not as a minimally invasive surgery, and adjuvant therapy is not administered 
to patients with intermediate-risk cervical cancer. The intermediate-risk group included patients with 2 or more of 
the following factors: tumor size >4 cm, stromal invasion >1/2, and lymphovascular stromal invasion. Intermediate-
risk patients with squamous cell carcinoma were included in the I-SCC group, whereas those with endocervical 
adenocarcinoma, usual type, or adenosquamous carcinoma were included in the I-Adeno group.
Results
There were 34 and 18 patients in the I-SCC and I-Adeno groups, respectively. The 5-year recurrence-free survival 
(RFS) and overall survival rates in the I-SCC group were 90.5% (95% confidence interval [CI], 85.3–95.7%) and 100% 
(95% CI, 100%), respectively, whereas those in the I-Adeno group were 54.9% (95% CI, 42.0–67.9%) and 76.1% 
(95% CI, 63.7–88.4%), respectively. Multivariate analysis revealed that endocervical adenocarcinoma, usual type, or 
adenosquamous carcinoma, and tumor size >4 cm had worse RFS.
Conclusion
The I-SCC group had good prognosis without adjuvant therapy; therefore, adjuvant therapy may be omitted in these 
patients. In contrast, the I-Adeno group had poor prognosis without adjuvant therapy; therefore, adjuvant therapy 
should be considered in their treatment.
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(GOG) 92 [1,2]. The GOG 92 trial showed that the adjuvant 
radiotherapy arm had improved progression-free survival 
compared to the surgery-only arm.
It has been pointed out that the GOG 92 trial had some 
limitations [3]. The GOG 92 trial was conducted more than 
20 years ago, and the diagnostic and treatment techniques 
were different from those used in the present. Tumor size 
was estimated visually, and recurrence in the surgery-only 
arm was poor compared to current expectations. Further-
more, the radiotherapy arm tended to have prolonged over-
all survival (OS) but did not show significant differences.
We do not perform adjuvant therapy for patients with 
intermediate-risk cervical cancer at our institution. The prog-
noses of patients show the baseline risks of recurrence and 
death, and the data are based on current diagnostic and 
therapeutic methods. To the best of our knowledge, prog-
nostic data for patients in the intermediate-risk group who 
had no adjuvant therapy are few in recent years [3,4]. We 
believe that our prognostic data are valuable for reviewing 
the GOG 92 trial. The present study aimed to investigate the 
prognosis of early cervical cancer patients with intermedi-
ate risk based on histological types. Moreover, we aimed to 
evaluate the necessity of adjuvant therapy.
Materials and methods
1. Treatment strategy in our institution
We performed type III radical hysterectomy with pelvic 
lymphadenectomy for stage IB–II cervical cancer classified 
according to the International Federation of Gynecology and 
Obstetrics (FIGO) 2008 system. Radical hysterectomy is per-
formed as an open surgery and not as a minimally invasive 
surgery in our institution. Patients with positive lymph node 
metastasis, positive parametrial invasion, or positive surgi-
cal margin received adjuvant concurrent chemoradiotherapy 
(CCRT), while the other patients did not.
2. Data collection
We collected cases of patients with stage IB–II (FIGO 2008) 
cervical cancer who underwent type III radical hysterectomy 
with pelvic lymphadenectomy between January 2008 and 
December 2017. Patients with positive lymph node metas-
tasis, positive parametrial invasion, positive surgical margins, 
and ovarian metastasis were excluded. The histological types 
included limited squamous cell carcinoma (SCC), endocervi-
cal adenocarcinoma, usual type (AC), and adenosquamous 
carcinoma (AS). Patients’ prognoses, and clinical and tumor 
pathological information were obtained from medical re-
cords, including age, body mass index (BMI), histological 
type, tumor size, stromal invasion, lymphovascular stromal 
invasion (LVSI), and vaginal invasion.
3. Statistical analysis
The low-risk group included patients with less than 2 and 
intermediate-risk group included patients with 2 or more of 
the following factors: tumor size >4 cm, stromal invasion 
>1/2, and LVSI. In the intermediate-risk group, the I-SCC 
group included patients with SCC, while the I-Adeno group 
included patients with AC or AS. Similarly, in the low-risk 
group, the L-SCC group comprised patients with SCC, while 
the L-Adeno group comprised patients with AC or AS.
Categorical variables were compared using the χ2 test, 
whereas continuous variables were compared using the 
Mann-Whitney U test. For survival analysis, recurrence-free 
survival (RFS) was defined as the period from the date of 
operation to the date of first recurrence or date of death due 
to any cause. OS was defined as the period from the date of 
operation to the date of death of any cause. Survival curves 
were constructed using the Kaplan-Meier method, and a uni-
variate log-rank test was used to assess the statistical signifi-
cance. Multivariate analyses for RFS were performed using 
the Cox proportional hazard model. All statistical analyses 
were performed using JMP® 15 (SAS Institute Inc., Cary, NC, 
USA).
Results
1.  Study population and clinicopathological 
characteristics
Overall, 213 patients with stage IB–II cervical cancer who 
underwent type III radical hysterectomy with pelvic lymph-
adenectomy were identified during the study period. Of the 
213 patients, 128 met the inclusion criteria and 85 were 
excluded, as they were classified into the high-recurrence 
group or as a rare histologic type (other than SCC, AC, or 
AS). A total of 52 patients were included in the intermediate-
risk group, with 34 patients in the I-SCC group and 18 in 
the I-Adeno group. There were 76 patients included in the 
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low-risk group, with 38 in the L-SCC group, and 38 in the 
L-Adeno group (Fig. 1). The characteristics of the I-SCC and 
I-Adeno groups are summarized in Table 1. The median age 
was 45 years (range, 25–63 years) and median BMI was 20.8 
(range, 16.8–29.8) in the I-SCC group, while in the I-Adeno 
group, the median age was 48 years (range, 39–66 years) 
and the median BMI was 20.6 (range, 17.2–34.2). Ten pa-
tients (29.4%) had a tumor size >4 cm, 33 patients (97.1%) 
had stromal invasion >1/2, 33 patients (97.1%) had positive 
LVSI, and 10 patients (29.4%) had positive vaginal invasion 
in the I-SCC group. Five patients (27.8%) had tumor size 
>4 cm, 17 patients (94.4%) had stromal invasion >1/2, 
16 patients (88.9%) had positive LVSI, and 6 patients (33.3%) 
had positive vaginal invasion in the I-Adeno group. No sig-
nificant differences in patient characteristics were observed 
between the I-SCC and I-Adeno groups. The characteristics 
of patients within the L-SCC and L-Adeno groups are sum-
marized in Supplementary Table 1. The L-Adeno group had 
a higher proportion of patients with positive vaginal invasion 
than the L-SCC group (P=0.04).
2. Survival analysis
The median follow-up period was 59 months (range, 2–131 
months). During the follow-up period, 3 (8.8%) patients 
had recurrence and no (0.0%) patients died in the I-SCC 
group, while 7 (38.9%) patients had recurrence and 3 
(17.6%) patients died in the I-Adeno group. Kaplan-Meier 
estimates of RFS and OS of the I-SCC and I-Adeno groups 
are presented in Fig. 2. The 5-year RFS and 5-year OS rates 
of the I-SCC group were 90.5% (95% confidence interval 
[CI], 85.3–95.7%) and 100% (95% CI, 100%), respectively. 
Fig. 1. Number of patients included for analysis. Thirty-four patients were in the intermediate-risk group with squamous cell carcinoma 
(I-SCC group) and 18 in the intermediate-risk group with endocervical adenocarcinoma, usual type, or adenosquamous carcinoma (I-Adeno 
group). Thirty-eight patients were in the low-risk group with squamous cell carcinoma (L-SCC group) and 38 in the low-risk group with 
endocervical adenocarcinoma, usual type, or adenosquamous carcinoma (L-Adeno group). a)Histologic type other than squamous cell car-
cinoma, adenocarcinoma, usual type, or adenosquamous carcinoma.
Patients with stage IB-II cervical cancer who underwent type III radical hysterectomy
with pelvic lymphadenectomy between January 2008 and December 2017 (n=213)
Intemediate-risk group (n=52)
I-SCC group (n=34) I-Adeno group (n=34)
Low-risk group (n=76)
L-SCC group (n=38) L-Adeno group (n=38)
High-risk group (n=68)
Rare histologyic typea) (n=17)







Age (yr) 45 (25–63) 48 (39–66) 0.41
BMI (kg/m2) 20.8 (16.8–29.8) 20.6 (17.2–34.2) 0.43
Tumor size (cm) 0.47
≤4 24 (70.6) 13 (72.2)
>4 10 (29.4) 5 (27.8)
Stromal invasion 0.30
≤1/2 1 (2.9) 1 (5.6)
>1/2 33 (97.1) 17 (94.4)
LVSI 0.44
Negative 1 (2.9) 2 (11.1)
Positive 33 (97.1) 16 (88.9)
Vaginal invasion 0.38
Negative 24 (70.6) 12 (66.7)
Positive 10 (29.4) 6 (33.3)
Values are presented as median (range) or number of patients (%).
I-SCC group, intermediate risk group with squamous cell carcinoma; 
I-Adeno group, intermediate risk group with endocervical adenocar-
cinoma, usual type, or adenosquamous carcinoma; BMI, body mass 
index; LVSI, lymphvascular space invasion.
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On the contrary, the 5-year RFS and 5-year OS rates of the I-
Adeno group were 54.9% (95% CI, 42.067.9%) and 76.1% 
(95% CI, 63.7–88.4%), respectively. Patients in the I-SCC 
group had significantly higher RFS and OS than those in the 
I-Adeno group (P<0.01, P=0.02). In the low-risk group, no 
patients had recurrence or died in the L-SCC group, and only 
1 patient had recurrence and no patients died in the L-Adeno 
group. There were no significant differences in RFS and OS 
between the I-SCC and L-SCC groups, while patients in the 
I-Adeno group had significantly lower RFS and OS than pa-
tients in the L-Adeno group (P<0.01, P<0.01). Kaplan-Meier 
estimates of RFS and OS of the I-Adeno and L-Adeno groups 
are presented in Fig. 3. Multivariate analysis with histologi-
cal type, tumor size, LVSI, and vaginal invasion revealed that 
histological type and tumor size had a significant effect on 
RFS (Table 2). Patients with AC or AS had low rates of RFS 
(hazard ratio [HR], 5.66; 95% CI, 1.38–23.22); patients with 
a tumor size >4 cm had low rates of RFS (HR, 9.68; 95% CI, 
2.57–36.42). As all patients who had recurrence had stromal 
invasion >1/2 in our study, the HR could not be calculated by 
the depth of stromal invasion. Thus, we did not include the 
depth of stromal invasion in the multivariate analysis.
Fig. 2. Kaplan-Meier estimates for recurrence-free survival (RFS) and overall survival (OS) of intermediate-risk group with squamous 
cell carcinoma (I-SCC group) and intermediate-risk group with endocervical adenocarcinoma, usual type, or adenosquamous carcinoma 
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Fig. 3. Kaplan-Meier estimates for recurrence-free survival (RFS) and overall survival (OS) of intermediate-risk group with endocervical 
adenocarcinoma, usual type, or adenosquamous carcinoma (I-Adeno group) and low-risk group with endocervical adenocarcinoma, usual 
type, or adenosquamous carcinoma (L-Adeno group). Patients in the I-Adeno group had significantly lower RFS and OS than those in the 
L-Adeno group (P<0.01, P<0.01).
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3.  The outcome of recurrence of cases in the 
intermediate-risk group with squamous cell 
carcinoma and intermediate-risk group with 
endocervical adenocarcinoma, usual type, or 
adenosquamous carcinoma
The outcomes of recurrence of cases in the I-SCC and 
I-Adeno groups are shown in Table 3. In the I-SCC group, 
3 patients had recurrent disease; 1 involved an intrapelvic 
lymph node, 1 involved a para-aortic lymph node, and 1 had 
vaginal stump recurrence and involved a para-aortic lymph 
node. These patients received salvage radiotherapy upon 
recurrence. In the I-Adeno group, 7 patients had recurrent 
disease; 5 had intrapelvic recurrence and 2 had extrapelvic 
recurrence, while 3 patients died.
Discussion
Our study showed the baseline recurrence risk of cervical 
cancer in the intermediate-risk group based on current diag-
nostic and therapeutic methods. Regarding SCC, the I-SCC 
group showed good prognosis without adjuvant therapy and 
had no significant differences in prognosis compared to the 
L-SCC group. On the contrary, the I-Adeno group showed a 
high recurrence rate without adjuvant therapy and had poor 
prognosis compared to the L-Adeno and I-SCC groups.
The criteria for categorizing patients in the intermediate-
risk group of cervical cancer are different in each guideline or 
study protocol. The National Comprehensive Cancer Network 
guidelines [5] introduced the Sedlis criteria for intermediate-
risk factors, which were adopted in the GOG 92 trial [1,2]. 
The guidelines defined the intermediate-risk group as in-
cluding patients with at least 2 of the following risk factors: 
1) greater than one-third stromal invasion, 2) capillary lym-
phatic space involvement, and 3) cervical tumor diameters of 
>4 cm. The Japan Society of Gynecologic Oncology (JSGO) 
Table 2. Multivariate analysis of clinicopathological factors and 
recurrence-free survival
Characteristics HR 95% CI P-value
Histology
SCC 1.00 - -
AC or AS 5.66 1.38–23.22 0.02
Tumor size (cm)
≤4 1.00 - -
>4 9.68 2.57–36.42 <0.01
LVSI
≤1/2 1.00 - -
>1/2 4.60 0.96–22.02 0.06
Vaginal invasion
Negative 1.00 - -
Positive 1.96 0.50–7.63 0.33
HR, hazard ratio; CI, confidence interval; SCC, squamous cell car-
cinoma; AC, endocervical adenocarcinoma, usual type; AS, adeno-
squamous carcinoma; LVSI, lymph-vascular space invasion.
Table 3. Outcome of recurrence cases in the intermediate risk group






38 SCC PLN 21 RT 104 Salvaged
32 SCC PALN 18 RT 22 Salvaged
42 SCC Vaginal stump and PALN 7 RT 59 Salvaged
52 AS Vagina 34 Brachytherapy 62 Salvaged
66 AC Vagina 13 Brachytherapy 56 DOD
44 AC Pelvic side wall 16 RT 48 DOD
49 AC Pelvic side wall 40 CCRT 92 Salvaged
41 AS Pelvic side wall 4 RT 34 DOD
48 AC Lung 28 No 48 AWD
56 AS Lung 9 Surgery 69 Salvaged
RFS, recurrence-free survival; SCC, squamous cell carcinoma; AS, adenosquamous carcinoma; AC, endocervical adenocarcinoma, usual type; 
PLN, pelvic lymph node; PALN, para-aortic lymph node; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; DOD, died of disease; AWD, 
alive with disease.
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guidelines define the intermediate-risk group as including 
patients with any of the following risk factors: 1) large tumor 
size, 2) deep stromal invasion, and 3) LVSI [6]. The Korean 
Gynecologic Oncology Group (KGOG) advocates a “4-factor 
model” that defines the intermediate-risk group as including 
patients with at least 2 of the following risk factors: 1) AC or 
AS, 2) tumor size ≥3 cm, 3) stromal invasion ≥outer 1/3, and 
4) LVSI [7]. We adopted the modified Sedlis criteria to sim-
plify the classification at our institution. The same patients 
would have been included in the present study even if we 
had adopted the original Sedlis criteria.
In the present study, the recurrence rate was 8.8% (3/34) 
in the I-SCC group, and all 3 patients were salvaged. The 
recurrence rate was lower than that of the surgery-only arm 
of the GOG 92 trial (27.8%, 32/115). Some of the factors 
for this difference may be the transition in preoperative diag-
nosis and the improvement of surgical techniques. Cibula et 
al. [3] showed the prognosis of the intermediate-risk group 
without adjuvant therapy. In the study, the intermediate-risk 
group was defined as cases that met the following criteria: 
LVSI and deep stromal invasion, LVSI and tumor size ≥2 cm, 
or tumor size ≥4 cm. The recurrence and mortality rates were 
6.3% (8/127) and 7.1% (9/127), respectively, and the 5-year 
RFS and 5-year OS rates were 94.5% and 95.7%, respective-
ly. These results are similar to our findings, besides the small 
difference in inclusion criteria. Furthermore, the prognosis 
of the no adjuvant therapy group was not inferior to that of 
the adjuvant radiotherapy group. The necessity of adjuvant 
therapy should be considered based on the baseline recur-
rence risk, efficacy of recurrence prevention, and complica-
tions arising in the treatment. Complications associated with 
radiotherapy included nausea, diarrhea, anemia, leg edema, 
ileus, lymphedema, and bone fracture, among others. The 
GOG 92 trial reported that grade 3 and 4 adverse events 
were seen in 7% of the radiotherapy arm, and other studies 
reported that adjuvant radiotherapy increased the occurrence 
of adverse events [1,2,8,9]. Regarding SCC, the benefit of 
adjuvant therapy for patients in the intermediate-risk group 
might be small, as the baseline recurrence and mortality rates 
were low. Adjuvant therapy might be omitted because it has 
little benefits and a considerable number of risks.
Lai et al. [10] reported no significant differences in RFS be-
tween adenocarcinoma and adenosquamous carcinoma, and 
Baek et al. [11] reported no differences in patterns of recur-
rence and time to recurrence. We analyzed AC, and AS to-
gether, as in the GOG 92 trial. The prognosis of the I-Adeno 
group was inferior to that of the I-SCC or L-Adeno groups, 
and multivariate analysis showed that AC or AS had worse 
RFS in the present study. Other studies also reported that the 
outcomes of cervical adenocarcinoma were inferior to that of 
SCC [12-14]. The “4-factor model,” suggested by the KGOG 
study as the new criteria for the intermediate-risk group, is 
unique compared to the Sedlis or JSGO criteria in that it con-
tains the criterion of histological type [5-7]. The histological 
type of the tumor was a significant prognostic factor in the 
present study. Our study showed that the 5-year RFS rate of 
the I-Adeno group was as poor as 54.9%. Because the base-
line recurrence risk of the I-Adeno group was high, adjuvant 
therapy should be considered in this case. Although the stan-
dard adjuvant therapy is radiotherapy based on the GOG 92 
trial, studies have reported the possibility that chemotherapy 
is as effective as adjuvant therapy for intermediate-risk cervi-
cal cancer [15-17]. Moreover, the efficacy of CCRT is being 
studied by GOG 263, which is an ongoing randomized con-
trolled trial comparing CCRT and radiotherapy as adjuvant 
therapy in patients with intermediate-risk cervical cancer. The 
results of a subgroup analysis of GOG 263 for adenocarcino-
ma are noteworthy, and we look forward to future research 
on adjuvant therapy for cervical adenocarcinoma.
The limitations of our study were the lack of an adjuvant 
therapy group and the small sample size. It is better to com-
pare the prognosis between the no-adjuvant and adjuvant 
therapy groups when we evaluate the effectiveness of adju-
vant therapy. To be precise, the benefit of adjuvant therapy 
was unclear in our study, but we consider that the low base-
line recurrence risk in the I-SCC group was one of the factors 
that could lead to omitting adjuvant therapy. Hence, more 
large-scale cohort studies that contain an adjuvant therapy 
group are warranted in the future to validate the findings of 
our study.
In conclusion, regarding SCC, patients with intermediate-
risk cervical cancer have good prognosis without adjuvant 
therapy; therefore, adjuvant therapy may be omitted. On the 
contrary, regarding adenocarcinoma, patients with intermedi-
ate-risk cervical cancer have poor prognosis without adjuvant 
therapy; adjuvant therapy should therefore be considered in 
the treatment. However, further large-scale studies are nec-
essary to validate the findings of the present study.
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